Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

1,999

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

1,999 results for “patient positioning”

Learn how ShareScore rates datasets ↗
zenodo40/100

Data for "Incidence, clinical course and risk factor for recurrent PCR positivity in discharged COVID-19 patients in Guangzhou, China: a prospective cohort study"

<p>Data for &quot;Incidence, clinical course and risk factor for recurrent PCR positivity in discharged COVID-19 patients in Guangzhou, China: a prospective cohort study&quot;</p>

opencc-by-4.0Aug 2020View details →
ClinicalTrials.gov40/100

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

ClinicalTrials.gov study NCT02336451. IPD Sharing: YES. Countries: 17. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

ClinicalTrials.gov study NCT01578239. IPD Sharing: YES. Countries: 8. Publications: 4.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.

ClinicalTrials.gov study NCT01844765. IPD Sharing: YES. Countries: 13. Publications: 3.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

ClinicalTrials.gov study NCT01828112. IPD Sharing: UNDECIDED. Countries: 20. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov40/100

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

ClinicalTrials.gov study NCT02684058. IPD Sharing: YES. Countries: 20. Publications: 4.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

ClinicalTrials.gov study NCT02450903. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thy

ClinicalTrials.gov study NCT04940052. IPD Sharing: YES. Countries: 11. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibito

ClinicalTrials.gov study NCT01610284. IPD Sharing: YES. Countries: 29. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

ClinicalTrials.gov study NCT02654587. IPD Sharing: NO. Countries: 10. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov40/100

Vertebral Artery and Cerebral Hemodynamics After Various Head Positions & Manipulation in Patients With Neck Pain

ClinicalTrials.gov study NCT02667821. IPD Sharing: YES. Countries: 1. Publications: 13.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

ClinicalTrials.gov study NCT00471497. IPD Sharing: YES. Countries: 35. Publications: 8.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

COVID-19 Patient Positioning Pragmatic Trial

ClinicalTrials.gov study NCT04359797. IPD Sharing: YES. Countries: 1. Publications: 14.

controlledIPD-YESFeb 2026View details →
zenodo36/100

Effectiveness of prone positioning in non-intubated ICU patients with moderate to severe ARDS

<p><strong>Data and R code from the paper</strong></p> <p><em><strong>Effectiveness of prone positioning in non-intubated ICU patients with moderate to severe ARDS</strong></em></p> <p>Authors:</p> <p>Manuel Taboada, Ph.D. Mariana Gonz&aacute;lez, M.D. Ant&iacute;a &Aacute;lvarez, M.D., Irene Gonz&aacute;lez, M.D, Javier Garc&iacute;a, M.D., Mar&iacute;a Eiras. M.D., Mar&iacute;a Diaz Vieito, M.D., Alberto Naveira, M.D., Pablo Otero, M.D., Olga Campa&ntilde;a, M.D., Ignacio Muniategui, M.D., Ana Tubio, M.D., Jose Costa, M.D., Salom&eacute; Selas, M.D., Agust&iacute;n Cari&ntilde;ena, M.D., Adri&aacute;n Mart&iacute;nez, M.D., Sonia Veiras, M.D. Ph.D, Francisco Aneiros, M.D., Valent&iacute;n Caruezo, M.D., Aurora Baluja, M.D. Julian Alvarez, Ph.D<br> <br> <strong>Background</strong>:<br> In the treatment for severe ARDS from COVID-19, the WHO recommends prone positioning (PP) during mechanical ventilation for periods of 12-16 hours per day to potentially improve oxygenation and survival. In this prospective observational study we evaluated the ability of long PP sessions to improve oxygenation in awake ICU patients with moderate or severe ARDS due to COVID-19.</p> <p><strong>Methods</strong>:<br> The study was approved by the ethics committee of Galicia (code No. 2020-188), and all patients provided informed consent. In this case series, awake patients with moderate or severe ARDS by COVID-19 admitted to the ICU at University Hospital of Santiago from March 21 to April 5, 2020 were prospectively analyzed. Patients were instructed to remain in PP as long as possible and not stop until the they felt too tired to maintain that position. If needed, light sedation was administered. The following information were collected: StO2 and blood gases (PaO2, PaO2/FiO2, PaCO2, pH) in ICU admission, number and duration of PP sessions, StO2 and blood gases before, during and following a PP session, need of mechanical ventilation, duration of ICU admission and ICU outcome. Linear mixed effects models (LMM) were adjusted to estimate changes of oxygenation parameters from baseline,. Patients were added as a random effect to account for inter-patient random variability in their own baseline measurements.</p> <p><strong>Results</strong>:<br> Seven patients with moderate or severe ARDS by COVID-19 were included. All patients received at least one PP session. A total of 16 PP sessions were performed in the 7 patients during the period study. The median duration of PP sessions was 10 hours. For PP sessions of more than 4 hours, dexmedetomidine was used for sedation. Oxygenation increased in all sixteen sessions performed in the seven patients. Prone positioning was associated to a net increase from baseline in PaO2, PaO2/FiO2 and StO2 (65, mmHg 110 and 2.6% respectively) PaO2/FiO2 increased during PP (&Delta; PaO2/FiO2 110.42 mmHg [28.173; 192.67]) and after PP (37.75 [-1.57; 77.07] compared with previous supine position (baseline PaO2FiO2 median-IQR97.8 [97.2 &ndash; 99.4]). Two patients required intubation. Six patients were discharged from the ICU and one remains on mechanical ventilation.</p> <p><strong>Conclusions</strong>:<br> We found that PP improved oxygenation and may avoid intubation in ICU patients with COVID-19 and moderate or severe ARDS. PP was relatively well tolerated in our patients. and may be a simple strategy to improve oxygenation trying to reduce patients in mechanical ventilation and the length of stay in the ICU, especially in the COVID-19 pandemic.</p> <p><strong>GitHub repository</strong>:</p> <p>https://github.com/medicalc/prone_sars</p>

opencc-by-4.0May 2020View details →
ClinicalTrials.gov36/100

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

ClinicalTrials.gov study NCT01937117. IPD Sharing: NO. Countries: 1. Publications: 2.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

ClinicalTrials.gov study NCT02111850. IPD Sharing: NO. Countries: 1. Publications: 3.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib

ClinicalTrials.gov study NCT05599334. IPD Sharing: Not stated. Countries: 5. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

ClinicalTrials.gov study NCT01625234. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

ClinicalTrials.gov study NCT02228382. IPD Sharing: YES. Countries: 8. Publications: 5.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

ClinicalTrials.gov study NCT02749903. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record